Clinical Trials
16 trialsNCT00064350 2023-06-29
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00600015 2022-03-10
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00647426 2019-10-22
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00754923 2019-03-06
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00801801 2017-05-17
Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
University of Alabama at Birmingham
Phase 2 Terminated
NCT00454194 2017-03-21
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00417248 2016-07-25
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00609804 2016-04-08
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00411671 2016-02-11
BATTLE Program: Sorafenib in Patients With NSCLC
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00449033 2015-04-23
NEXUS
Bayer
Phase 3 Completed
NCT00863746 2015-01-19
MISSION
Bayer
Phase 3 Completed
NCT00300885 2014-11-04
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Bayer
Phase 3 Terminated
NCT00558636 2013-12-27
A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Bayer
Phase 3 Terminated
NCT00101413 2013-10-30
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
Bayer
Phase 2 Completed
NCT00098254 2012-05-02
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed